Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 2
2009 2
2010 4
2011 5
2012 6
2013 2
2014 4
2015 6
2016 6
2017 1
2018 4
2019 9
2020 7
2021 6
2022 4
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Results by year

Filters applied: . Clear all
Page 1
HER2-Targeted Therapy in Osteosarcoma.
Gill J, Hingorani P, Roth M, Gorlick R. Gill J, et al. Among authors: hingorani p. Adv Exp Med Biol. 2020;1257:55-66. doi: 10.1007/978-3-030-43032-0_5. Adv Exp Med Biol. 2020. PMID: 32483730 Review.
Progress of oncolytic viruses in sarcomas.
Lettieri CK, Hingorani P, Kolb EA. Lettieri CK, et al. Among authors: hingorani p. Expert Rev Anticancer Ther. 2012 Feb;12(2):229-42. doi: 10.1586/era.11.205. Expert Rev Anticancer Ther. 2012. PMID: 22316371 Review.
Oncolytic viruses for potential osteosarcoma therapy.
Hingorani P, Sampson V, Lettieri C, Kolb EA. Hingorani P, et al. Adv Exp Med Biol. 2014;804:259-83. doi: 10.1007/978-3-319-04843-7_14. Adv Exp Med Biol. 2014. PMID: 24924179 Review.
Trastuzumab Deruxtecan, Antibody-Drug Conjugate Targeting HER2, Is Effective in Pediatric Malignancies: A Report by the Pediatric Preclinical Testing Consortium.
Hingorani P, Zhang W, Zhang Z, Xu Z, Wang WL, Roth ME, Wang Y, Gill JB, Harrison DJ, Teicher BA, Erickson SW, Gatto G, Kolb EA, Smith MA, Kurmasheva RT, Houghton PJ, Gorlick R. Hingorani P, et al. Mol Cancer Ther. 2022 Aug 2;21(8):1318-1325. doi: 10.1158/1535-7163.MCT-21-0758. Mol Cancer Ther. 2022. PMID: 35657346
Phase 2 study of anti-disialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma: A report from the Children's Oncology Group.
Hingorani P, Krailo M, Buxton A, Hutson P, Sondel PM, Diccianni M, Yu A, Morris CD, Womer RB, Crompton B, Randall RL, Teot LA, DuBois SG, Janeway KA, Gorlick RG, Isakoff MS. Hingorani P, et al. Eur J Cancer. 2022 Sep;172:264-275. doi: 10.1016/j.ejca.2022.05.035. Epub 2022 Jul 6. Eur J Cancer. 2022. PMID: 35809374 Free PMC article. Clinical Trial.
Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group.
Roberts RD, Lizardo MM, Reed DR, Hingorani P, Glover J, Allen-Rhoades W, Fan T, Khanna C, Sweet-Cordero EA, Cash T, Bishop MW, Hegde M, Sertil AR, Koelsche C, Mirabello L, Malkin D, Sorensen PH, Meltzer PS, Janeway KA, Gorlick R, Crompton BD. Roberts RD, et al. Among authors: hingorani p. Cancer. 2019 Oct 15;125(20):3514-3525. doi: 10.1002/cncr.32351. Epub 2019 Jul 29. Cancer. 2019. PMID: 31355930 Free PMC article. Review.
59 results